Biohaven (BHVN)

• Market cap: $1.58B
• 1 day: -0.83%
• 5 days: -12.51%
• 1 month: -20.76%
• 3 months: -45.22%
• 6 months: -59.81%
• Year to date: -58.53%
• 1 year: -53.73%
• 5 years: 111.78%
• 10 years: 111.78%
• Sector: Healthcare
• Industry: Biotechnology

About: Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

Employees: 256

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

304% more call options, than puts

Call options by funds: $30.7M | Put options by funds: $7.59M

25% more repeat investments, than reductions

Existing positions increased: 95 | Existing positions reduced: 76

24% more first-time investments, than exits

New positions opened: 47 | Existing positions closed: 38

2% more funds holding

Funds holding: 255 [Q4 2024] → 261 (+6) [Q1 2025]

3.41% less ownership

Funds ownership: 92.02% [Q4 2024] → 88.61% (-3.41%) [Q1 2025]

20% less funds holding in top 10

Funds holding in top 10: 10 [Q4 2024] → 8 (-2) [Q1 2025]

37% less capital invested

Capital invested by funds: $3.51B [Q4 2024] → $2.22B (-$1.29B) [Q1 2025]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $21 36% upside
• Avg. target: $39 152% upside
• High target: $57 269% upside

2 analyst ratings

• positive: 1 50%
• neutral: 1 50%
• negative: 0 0%

RBC Capital Leonid Timashev	36% upside $21	Sector Perform Downgraded	19 May 2025
Baird Brian Skorney	269% upside $57	Outperform Maintained	28 Apr 2025